Michael Maitland is an Oncology physician affiliated with Program for Appropriate Technology in Health. OpenAlex indexes 213 publications with 8,646 citations (h-index 37); ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8081 Innovation Park Dr
Fairfax, VA 220314867
Telephone
571-472-4724Provider last certified this registry record 16 Oct 2020.
Clinical trials
- High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors
Sponsor: National Cancer Institute (NCI)
- Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
Sponsor: National Cancer Institute (NCI)
- Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC
Sponsor: University of Chicago
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20241 payment
- PFIZER INC.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2016–2020 per NIH RePORTER. The latest:
- Computational modeling of tumor burden by CT to advance cancer therapeutics
Inova Health Care Services
FY2020$558,237R01CA194783 - Computational modeling of tumor burden by CT to advance cancer therapeutics
Inova Health Care Services
FY2019$556,187R01CA194783 - Computational modeling of tumor burden by CT to advance cancer therapeutics
Inova Health Care Services
FY2018$573,026R01CA194783
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- CRISPR-Cas9 In Vivo Gene Editing of <i>KLKB1</i> for Hereditary Angioedema
New England Journal of Medicine
2024 - CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis
Yearbook of pediatric endocrinology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Christian Ockenhouse, MD
Program for Appropriate Technology in Health
Niranjan Bhat, MD
Program for Appropriate Technology in Health
Smita Das, MD, PhD, MPH
Program for Appropriate Technology in Health
John Minarcik, MD
Program for Appropriate Technology in Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”